The bad news keeps coming for NeoPharm. Researchers announced late Friday that its experimental colon cancer drug, LE-SN38, missed its primary tumor-response endpoint in a mid-stage trial. No new patients will be enrolled but patients already receiving the therapy will continue to gets doses. The news comes after the company announced last week it was replacing its CEO after being informed that the company would have to mount a new late-stage study of its brain cancer therapy before it could be considered for approval. Report